secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0000950170-22-009670
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q1 net loss $21.0M; topline ACT-AD Phase 2 data by end of 2Q22
----------------------------------------------------------------------------

- Net loss $21.0M ($0.56/share) vs $8.9M ($0.25/share) in Q1 2021; R&D expense $14.5M, up from $7.4M.
- Cash, equivalents & investments $301.2M at March 31, 2022 vs $319.7M at December 31, 2021.
- Topline ACT-AD Phase 2 data in mild-to-moderate Alzheimer's expected by end of Q2 2022.
- LIFT-AD Phase 3 enrollment target increased to ~420 patients; completion expected in Q3 2022.
- Dosed first patient in SHAPE Phase 2 trial for Parkinson's disease dementia and Dementia with Lewy bodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022009670/0000950170-22-009670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017022009670/atha-20220512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer